Trial Profile

A real-world compassionate use program study of CPX-351 in patients with acute myeloid leukemia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

14 Dec 2021 Results from the extended follow up analysis of the Italian CUP presented at the 63rd American Society of Hematology Annual Meeting and Exposition
21 Jun 2020 Results (n=73) assessing clinical activity and tolerability of CPX-351 in a poor risk AML cohort presented at the 25th Congress of the European Haematology Association
28 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com